Tailwinds' Take: Scientists of this caliber don't join SABs unless there's something exciting going on. We eagerly anticipate the release of Non-Human Primate data sometime (hopefully) soon. RICHMOND, British Columbia &  GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company...
When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving, technology. The management team is strong and the board is outstanding. All the pieces were...
Tailwinds' Take: having a manufacturing partner is a key step towards clinical development of their drug candidates. With their recent financing, which we believe had large insider participation, behind them, we would expect to see more press releases out...
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key...
Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver, British Columbia. The total number of shares represented in person or by proxy at the...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain...
Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not only reveal their sales and profits, but, typically, they provide guidance (either specifically or in...
Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded and on Nasdaq, Bioasis should start to attract some real investor attention. We entered early...
Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has never gotten the traction needed with financing and, frankly, our communications with him have been...
This week Bioasis heard back from the FDA on written questions they had submitted. These questions concern their lead investigational candidate xB3-001 and its development path. The Company’s goal, of course, is to bring this therapeutic into clinical development...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.